Back    Zoom +    Zoom -
FOSUN PHARMA (02196.HK), BioNTech Start COVID-19 Vaccine Trial in China
Recommend
27
Positive
71
Negative
24
2020/08/05 17:17
FOSUN PHARMA (02196.HK) and BioNTech announced that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA).

FOSUN PHARMA and BioNTech are jointly developing the COVID-19 vaccine candidate in China. The trial is part of BioNTech’s global development program aimed at supporting a global supply upon regulatory approval.

Related NewsCiti Latest Ratings, TPs on CN Medical Sector (Table)

AAStocks Financial News
Web Site: www.aastocks.com